Early carbon dioxide challenge test may predict clinical response in panic disorder

Area of Science:

• Neuroscience
• Clinical Psychology
• Pharmacology

Background:

• Panic disorder is a debilitating condition characterized by recurrent, unexpected panic attacks.
• The carbon dioxide (CO(2)) challenge test is used to provoke panic attacks and study panic disorder.
• Predicting clinical response to treatment is crucial for effective panic disorder management.

Purpose of the Study:

• To investigate the correlation between responses to the carbon dioxide (CO(2)) challenge test and clinical outcomes in panic disorder patients.
• To assess if the CO(2) challenge test can serve as a predictor of treatment response.
• To evaluate the effect of clonazepam on panic attack provocation by CO(2).

Main Methods:

• Thirty-four patients diagnosed with panic disorder were enrolled in the study.
• Participants underwent the CO(2) challenge test at baseline, 1 hour, 2 weeks, and 6 weeks of treatment.
• Treatment involved either clonazepam (2 mg/day) or a placebo.

Main Results:

• Patients receiving clonazepam exhibited significantly fewer panic attacks in response to the CO(2) challenge test compared to the placebo group.
• A notable correlation was observed between the reduction in panic attack frequency during the CO(2) test and overall clinical improvement.
• The CO(2) challenge test demonstrated potential as a predictive measure for treatment response.

Conclusions:

• The findings suggest that the CO(2) challenge test response is associated with clinical response in panic disorder.
• Clonazepam appears to attenuate the panicogenic effects of CO(2), indicating a potential mechanism of action.
• The CO(2) challenge test may be a valuable tool for predicting treatment efficacy in panic disorder management.